ClinicalTrials.gg
RecruitingNCT06501443Updated Dec 30, 2025

LATAM LOWERS LDL-C

A Phase 4 interventional study of Usual care and KJX839 in Hypercholesterolaemia, sponsored by Novartis Pharmaceuticals. Recruiting at 11 sites in 2 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
520
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing inclisiran in Hypercholesterolemia — 6 open to participants now, 10 under way, 5 of them phase 3. inclisiran · Hypercholesterolemia.

Planned enrollment
8th of 24
520 · median 375
Started
2025
with 2 others
Phase 4
7 of 24
3 open now
Registered
19th of 24
by date
Lead sponsor
16 of 24
Novartis Pharmaceuticals

Among the 24 studies testing inclisiran in Hypercholesterolemia, this one is the 8th largest by planned enrollment, is one of 3 that started in 2025, is one of 7 in phase 4, and was the 19th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

6 of the 24 studies testing inclisiran in Hypercholesterolemia are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About inclisiran

inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing inclisiran in Hypercholesterolemia, or all of them as a file.
02

Study summary

This is an open label, patient-level 1:1 randomized clinical trial in a multi-country study aiming to evaluate the real-world impact of inclisiran + Usual Care (UC) vs UC alone on LDL-C lowering, patient-reported outcomes, and healthcare resource utilization in an in-hospital population of patients, admitted during the acute setting, stabilized and before discharge, following an acute cardiovascular event.

Read the detailed description

The primary objective is to evaluate the impact of inclisiran plus usual care on LDL-C lowering versus usual care after acute MI, confirmed ischemic stroke, or urgent coronary revascularization.

The secondary objective is to compare the LDL-C reduction of both arms in target population.

Study completion for an individual participant is defined as when the participant finishes the last visit (day 330) and any assessments associated with that visit.

03

Conditions studied

  • Hypercholesterolaemia

Keywords

  • PCSK9i
  • hypercholesterolemia
  • atherosclerotic cardiovascular disease
  • LDL-cholesterol
  • Latin America
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admitted for MI (Type 1 NSTEMI or STEMI), urgent (i.e., non-elective) coronary revascularization (PCI or CABG) or confirmed ischemic stroke.
  • Stable patient: Patient will be considered stable if they did not suffer cardiac arrest at presentation or if in the last 24 hours before randomization:

    • Was not in cardiogenic shock.
    • Did not required invasive hemodynamic, inotropic or vasopressor support.
  • Participants are required to be eligible for receiving inclisiran in accordance to approved local label.

    • Of note, patients who are initiated on statin therapy during the same hospitalization will not be excluded, as we expect a proportion of patients at baseline to not yet be on statin therapy in this real-world study. This will enhance the generalizability and pragmatic aspects of the study. However, because initiation of statin therapy at or near the time of enrollment could impact the primary outcome (if there is imbalance between the arms, or if there is differential stopping of statin therapy between the arms), we will stratify randomization by this factor and will pre-specify analyses in those who have vs. have not been initiated on statin therapy during the same hospitalization.

Exclusion criteria

Exclusion Criteria:

  • Currently on PCSK9i therapy (within last 3 months)
  • Current participation in another clinical study with another study drug
  • Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver at the Baseline Visit
  • Pregnant or nursing (lactating) women
  • Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
520 participants (estimated)

Study arms

  • Active comparator
    Usual Care

    Patients will receive what is the usual care in their respective countries. Usual care includes physical activity, diet modification, pharmacological therapy as: statin therapy (rosuvastatin, atorvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin), ezetimibe, cholestyramine or bempedoic acid.

    Drug: Usual care

  • Experimental
    Inclisiran + Usual Care

    Patients will receive what is usual care in their countries plus inclisiran 284 mg at baseline, 90 days, and 270 days.

    Drug: Usual care · Drug: KJX839

Interventions

  • DrugUsual care

    Treatment after acute event approved in the country where patient is based. It may include educational intervention according to each country guidelines

  • DrugKJX839

    Inclisiran in solution for subcutaneous injection on day 1, day 90, and day 270

    Also known as: Inclisiran

06

What researchers measure

Primary outcomes

  1. Change in LDL-C from baseline to 330 days

    Impact of inclisiran plus usual care on low-density lipoprotein cholesterol (LDL-C) lowering versus usual care after acute myocardial infarction (MI), confirmed ischemic stroke, or urgent coronary revascularization. The "baseline" level will be measured according to: * Baseline LDL-C from Standard of Care: If an LDL-C measurement has already been conducted as part of the standard care practices upon the patient's admission (prior to considering enrollment in the study), this measurement is considered the baseline value for the study. * Baseline LDL-C for Enrolled Patients: In cases where LDL-C was not performed as part of standard care at admission, the baseline LDL-C measurement will be drawn during 'Visit 0' after the patient has provided informed consent.

    Time frame: Baseline and Day 330

Secondary outcomes

  1. Proportion of patients with >=50% reduction in LDL-C from baseline.

    The "baseline" level will be measured according to: * Baseline LDL-C from Standard of Care: If an LDL-C measurement has already been conducted as part of the standard care practices upon the patient's admission (prior to considering enrollment in the study), this measurement is considered the baseline value for the study. * Baseline LDL-C for Enrolled Patients: In cases where LDL-C was not performed as part of standard care at admission, the baseline LDL-C measurement will be drawn during 'Visit 0' after the patient has provided informed consent.

    Time frame: Baseline and Day 330

  2. Proportion of patients achieving LDL-C goal of <70 mg/dL

    Reducing LDL-C to a threshold of at least 70 mg/dL is a cornerstone of secondary prevention therapy, and is recommended by major international guidelines.

    Time frame: Baseline and Day 330

  3. Among participants with a baseline LDL-C≥55 mg/dL: Proportion of patients achieving LDL-C goal of <55 mg/dL

    The "baseline" level will be measured according to: * Baseline LDL-C from Standard of Care: If an LDL-C measurement has already been conducted as part of the standard care practices upon the patient's admission (prior to considering enrollment in the study), this measurement is considered the baseline value for the study. * Baseline LDL-C for Enrolled Patients: In cases where LDL-C was not performed as part of standard care at admission, the baseline LDL-C measurement will be drawn during 'Visit 0' after the patient has provided informed consent.

    Time frame: Baseline and Day 330

  4. Number of participants by timing of statin initiation

    Number of participants by statin initiated during index hospitalization vs. not.

    Time frame: Up to 330 days

07

Study locations

10 of 11 sites recruiting
  • Novartis Investigative Site
    Corrientes, W3400CDS, Argentina
    Recruiting
  • Novartis Investigative Site
    Salvador, Estado de Bahia 40170-130, Brazil
    Recruiting
  • Novartis Investigative Site
    Belo Horizonte, Minas Gerais 30000, Brazil
    Recruiting
  • Novartis Investigative Site
    Belo Horizonte, Minas Gerais 30110-934, Brazil
    Recruiting
  • Novartis Investigative Site
    Campo Largo, Paraná 83606-177, Brazil
    Recruiting
  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90560-032, Brazil
    Recruiting
  • Novartis Investigative Site
    Blumenau, Santa Catarina 89010-500, Brazil
    Withdrawn

    Not enrolling at this site.

  • Novartis Investigative Site
    São José, Santa Catarina 88103-901, Brazil
    Recruiting
  • Novartis Investigative Site
    São José, São Paulo 15015-110, Brazil
    Recruiting
  • Novartis Investigative Site
    Campina Gde Do Sul, 83430 000, Brazil
    Recruiting
  • Novartis Investigative Site
    Salvador, 40323-010, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Nov 2026, 21 months after the start.

Of 40 phase 4 interventional studies under Hypercholesterolemia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 21 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2024
First posted
Jul 15, 2024
StartActual
Feb 11, 2025
Primary completionEst.
Nov 27, 2026
CompletionEst.
Nov 29, 2026
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06501443
Responsible party
Sponsor
First posted
Jul 15, 2024
Start date
Feb 11, 2025
Primary completion
Nov 27, 2026 (estimated)
Completion
Nov 29, 2026 (estimated)
Last update
Dec 30, 2025

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion